Roivant Sciences Ltd (ROIV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 7,990 | -8,121 | 15,562 | 3,648 | 21,624 |
| Cost of Goods | 213 | -3,035 | 197 | 223 | 4,214 |
| Gross Profit | 7,777 | -5,086 | 15,365 | 3,425 | 17,410 |
| Operating Expenses | 110,225 | 134,998 | -5,111,893 | 217,539 | 294,037 |
| Operating Income | -102,235 | -140,119 | 5,127,455 | -213,891 | -276,413 |
| Interest Expense | 0 | 0 | 0 | 0 | 8,912 |
| Other Income | 82,595 | 121,929 | 26,090 | -27,515 | -40,768 |
| Pre-tax Income | -19,640 | -18,190 | 5,153,545 | -241,406 | -326,093 |
| Income Tax | 11,963 | -5,850 | 22,365 | 3,236 | 1,752 |
| Net Income Continuous | -31,603 | -12,340 | 5,131,180 | -244,642 | -327,845 |
| Net Income Discontinuous | 89,093 | -170,156 | -58,515 | -86,476 | N/A |
| Minority Interests | -37,807 | -31,381 | -23,519 | -26,791 | -36,029 |
| Net Income | $95,297 | $-151,115 | $5,096,184 | $-304,327 | $-291,816 |
| EPS Basic Total Ops | 0.13 | -0.04 | 6.37 | -0.40 | -0.38 |
| EPS Basic Continuous Ops | -0.04 | 0.14 | 6.41 | -0.32 | -0.43 |
| EPS Basic Discontinuous Ops | 0.12 | -0.22 | -0.07 | -0.11 | N/A |
| EPS Diluted Total Ops | 0.12 | -0.02 | 6.03 | -0.40 | -0.38 |
| EPS Diluted Continuous Ops | -0.04 | 0.14 | 6.08 | -0.32 | -0.43 |
| EPS Diluted Discontinuous Ops | 0.11 | -0.20 | -0.07 | -0.11 | N/A |
| EPS Diluted Before Non-Recurring Items | -0.24 | -0.28 | -0.26 | N/A | N/A |
| EBITDA(a) | $-97,352 | $-134,894 | $5,132,840 | $-208,304 | $-270,574 |